Published in J Pediatr Hematol Oncol on March 01, 2004
Hydroxyurea to Prevent Organ Damage in Children With Sickle Cell Anemia | NCT00006400
Hydroxycarbamide in very young children with sickle-cell anaemia: a multicentre, randomised, controlled trial (BABY HUG). Lancet (2011) 7.30
How I use hydroxyurea to treat young patients with sickle cell anemia. Blood (2010) 2.68
The pediatric hydroxyurea phase III clinical trial (BABY HUG): challenges of study design. Pediatr Blood Cancer (2010) 2.36
Long-term hydroxyurea therapy for infants with sickle cell anemia: the HUSOFT extension study. Blood (2005) 1.99
Adherence to hydroxyurea therapy in children with sickle cell anemia. J Pediatr (2009) 1.91
Hydroxyurea for children with sickle cell disease. Hematol Oncol Clin North Am (2010) 0.98
Hydroxyurea for the treatment of sickle cell disease: efficacy, barriers, toxicity, and management in children. Pediatr Blood Cancer (2012) 0.93
Cyanide, peroxide and nitric oxide formation in solutions of hydroxyurea causes cellular toxicity and may contribute to its therapeutic potency. J Mol Biol (2009) 0.89
Minireview: Prognostic factors and the response to hydroxurea treatment in sickle cell disease. Exp Biol Med (Maywood) (2016) 0.88
Prevention of conversion to abnormal transcranial Doppler with hydroxyurea in sickle cell anemia: A Phase III international randomized clinical trial. Am J Hematol (2015) 0.85
Hydroxyurea Therapy for Children With Sickle Cell Anemia in Sub-Saharan Africa: Rationale and Design of the REACH Trial. Pediatr Blood Cancer (2015) 0.80
Hydroxyurea in sickle cell disease: drug review. Indian J Hematol Blood Transfus (2013) 0.79
Massive accidental overdose of hydroxyurea in a young child with sickle cell anemia. Pediatr Blood Cancer (2011) 0.75
Hydroxycarbamide in very young children with sickle-cell anaemia: a multicentre, randomised, controlled trial (BABY HUG). Lancet (2011) 7.30
The effect of ligand efficacy on the formation and stability of a GPCR-G protein complex. Proc Natl Acad Sci U S A (2009) 2.86
Sustained long-term hematologic efficacy of hydroxyurea at maximum tolerated dose in children with sickle cell disease. Blood (2003) 2.55
The pediatric hydroxyurea phase III clinical trial (BABY HUG): challenges of study design. Pediatr Blood Cancer (2010) 2.36
Pulmonary hypertension and nitric oxide depletion in sickle cell disease. Blood (2010) 2.25
Hydroxyurea therapy lowers transcranial Doppler flow velocities in children with sickle cell anemia. Blood (2007) 2.13
Childhood autoimmune cytopenia secondary to unsuspected common variable immunodeficiency. J Pediatr (2003) 2.11
A prospective newborn screening and treatment program for sickle cell anemia in Luanda, Angola. Am J Hematol (2013) 2.06
R2* magnetic resonance imaging of the liver in patients with iron overload. Blood (2009) 2.05
Mutations in the gene encoding the lamin B receptor produce an altered nuclear morphology in granulocytes (Pelger-Huët anomaly). Nat Genet (2002) 1.99
Long-term hydroxyurea therapy for infants with sickle cell anemia: the HUSOFT extension study. Blood (2005) 1.99
In vitro modeling of the microvascular occlusion and thrombosis that occur in hematologic diseases using microfluidic technology. J Clin Invest (2011) 1.89
Clinical course and flow cytometric analysis of paroxysmal nocturnal hemoglobinuria in the United States and Japan. Medicine (Baltimore) (2004) 1.67
Impact of hydroxyurea on clinical events in the BABY HUG trial. Blood (2012) 1.66
Arterial spin-labeled perfusion combined with segmentation techniques to evaluate cerebral blood flow in white and gray matter of children with sickle cell anemia. Pediatr Blood Cancer (2009) 1.60
Organic anion transporting polypeptide 1B transporters modulate hydroxyurea pharmacokinetics. Am J Physiol Cell Physiol (2013) 1.56
Hydroxyurea therapy of a murine model of sickle cell anemia inhibits the progression of pneumococcal disease by down-modulating E-selectin. Blood (2011) 1.54
Genetic mapping and exome sequencing identify 2 mutations associated with stroke protection in pediatric patients with sickle cell anemia. Blood (2013) 1.52
Enalapril and hydroxyurea therapy for children with sickle nephropathy. Pediatr Blood Cancer (2005) 1.51
A pilot study of hydroxyurea to prevent chronic organ damage in young children with sickle cell anemia. Pediatr Blood Cancer (2009) 1.50
Pain and other non-neurological adverse events in children with sickle cell anemia and previous stroke who received hydroxyurea and phlebotomy or chronic transfusions and chelation: results from the SWiTCH clinical trial. Am J Hematol (2013) 1.49
Bone marrow transplant options and preferences in a sickle cell anemia cohort on chronic transfusions. Pediatr Blood Cancer (2012) 1.46
Hydroxyurea for children with sickle cell disease. Pediatr Clin North Am (2008) 1.43
Red blood cell alloimmunization in sickle cell disease: pathophysiology, risk factors, and transfusion management. Blood (2012) 1.43
SUMO modification regulates inactivation of the voltage-gated potassium channel Kv1.5. Proc Natl Acad Sci U S A (2007) 1.39
Silent cerebral infarcts: a review on a prevalent and progressive cause of neurologic injury in sickle cell anemia. Blood (2012) 1.37
Preservation of spleen and brain function in children with sickle cell anemia treated with hydroxyurea. Pediatr Blood Cancer (2008) 1.30
Hemozoin-generated vapor nanobubbles for transdermal reagent- and needle-free detection of malaria. Proc Natl Acad Sci U S A (2013) 1.28
Biomarkers of splenic function in infants with sickle cell anemia: baseline data from the BABY HUG Trial. Blood (2011) 1.26
Assessment of genotoxicity associated with hydroxyurea therapy in children with sickle cell anemia. Mutat Res (2010) 1.24
Hydroxyurea adherence and associated outcomes among Medicaid enrollees with sickle cell disease. Am J Hematol (2011) 1.19
Hydroxyurea for sickle cell anemia: what have we learned and what questions still remain? Curr Opin Hematol (2011) 1.18
Clinical and hematologic benefits of partial splenectomy for congenital hemolytic anemias in children. Ann Surg (2003) 1.18
Lipopolysaccharide-induced cyclooxygenase-2 expression in human U937 macrophages is phosphatidic acid phosphohydrolase-1-dependent. J Biol Chem (2006) 1.15
Glomerular hyperfiltration and albuminuria in children with sickle cell anemia. Pediatr Nephrol (2011) 1.14
Genetic predictors for stroke in children with sickle cell anemia. Blood (2011) 1.12
Real-time detection of basal and stimulated G protein GTPase activity using fluorescent GTP analogues. J Biol Chem (2004) 1.12
Hydroxyurea therapy requires HbF induction for clinical benefit in a sickle cell mouse model. Haematologica (2010) 1.10
Effect of hydroxyurea on growth in children with sickle cell anemia: results of the HUG-KIDS Study. J Pediatr (2002) 1.07
Quantitative analysis of Howell-Jolly bodies in children with sickle cell disease. Exp Hematol (2007) 1.06
Urine concentrating ability in infants with sickle cell disease: baseline data from the phase III trial of hydroxyurea (BABY HUG). Pediatr Blood Cancer (2010) 1.06
Genetic modifiers of sickle cell anemia in the BABY HUG cohort: influence on laboratory and clinical phenotypes. Am J Hematol (2013) 1.06
Malignancy in patients with sickle cell disease. Am J Hematol (2003) 1.03
Effect of hydroxyurea treatment on renal function parameters: results from the multi-center placebo-controlled BABY HUG clinical trial for infants with sickle cell anemia. Pediatr Blood Cancer (2012) 1.02
Neurocognitive development of young children with sickle cell disease through three years of age. J Pediatr Psychol (2002) 1.02
Hydroxyurea treatment decreases glomerular hyperfiltration in children with sickle cell anemia. Am J Hematol (2012) 1.02
Chromosome damage and repair in children with sickle cell anaemia and long-term hydroxycarbamide exposure. Br J Haematol (2011) 0.99
Hydroxyurea for children with sickle cell disease. Hematol Oncol Clin North Am (2010) 0.98
Long-term results using hydroxyurea/phlebotomy for reducing secondary stroke risk in children with sickle cell anemia and iron overload. Am J Hematol (2011) 0.98
Genotoxicity associated with hydroxyurea exposure in infants with sickle cell anemia: results from the BABY-HUG Phase III Clinical Trial. Pediatr Blood Cancer (2011) 0.96
ARF6 activation by Galpha q signaling: Galpha q forms molecular complexes with ARNO and ARF6. Cell Signal (2006) 0.95
Is sickle cell anemia a neglected tropical disease? PLoS Negl Trop Dis (2013) 0.93
Severe thrombocytopenia with iron deficiency anemia. Pediatr Hematol Oncol (2010) 0.93
The natural history of conditional transcranial Doppler flow velocities in children with sickle cell anaemia. Br J Haematol (2008) 0.93
Partial splenectomy for hereditary spherocytosis: a multi-institutional review. J Pediatr Surg (2011) 0.92
Simultaneous acute splenic sequestration and transient aplastic crisis in children with sickle cell disease. Pediatr Blood Cancer (2009) 0.91
Ventricular diastolic dysfunction in sickle cell anemia is common but not associated with myocardial iron deposition. Pediatr Blood Cancer (2010) 0.90
A pilot study of subcutaneous decitabine in β-thalassemia intermedia. Blood (2011) 0.88
Chronic transfusion practice for children with sickle cell anaemia and stroke. Br J Haematol (2008) 0.88
Brown recluse spider (Loxosceles reclusa) envenomation leading to acute hemolytic anemia in six adolescents. J Pediatr (2010) 0.88
Subclinical parvovirus B19 infection in children with sickle cell anemia. J Pediatr Hematol Oncol (2003) 0.88
Transcellular movement of hydroxyurea is mediated by specific solute carrier transporters. Exp Hematol (2011) 0.87
Current management of sickle cell anemia. Cold Spring Harb Perspect Med (2013) 0.87
Chemical and functional analysis of generic hydroxyurea formulations. Pediatr Hematol Oncol (2008) 0.86
Transfusional iron overload in children with sickle cell anemia on chronic transfusion therapy for secondary stroke prevention. Am J Hematol (2011) 0.86
Epigenetic and molecular profiles of erythroid cells after hydroxyurea treatment in sickle cell anemia. Blood (2011) 0.86
Hemodynamic responses to visual stimulation in children with sickle cell anemia. Brain Imaging Behav (2011) 0.86
Sickle cell disease caused by heterozygosity for Hb S and novel LCR deletion: Report of two patients. Am J Hematol (2009) 0.86
Chlamydia pneumoniae and acute chest syndrome in patients with sickle cell disease. J Pediatr Hematol Oncol (2003) 0.86
Successful use of anti-CD20 (rituximab) in severe, life-threatening childhood immune thrombocytopenic purpura. J Pediatr (2003) 0.85
UGT1A1 promoter polymorphisms and the development of hyperbilirubinemia and gallbladder disease in children with sickle cell anemia. Am J Hematol (2008) 0.84
Identification of hemochromatosis gene polymorphisms in chronically transfused patients with sickle cell disease. Am J Hematol (2003) 0.84
Hemoglobinopathies mimicking Hb S/beta-thalassemia: Hb S/S with alpha-thalassemia and Hb S/Volga. Am J Hematol (2006) 0.84
UGT1A promoter polymorphisms influence bilirubin response to hydroxyurea therapy in sickle cell anemia. J Lab Clin Med (2003) 0.84
Novel Use of Hydroxyurea in an African Region With Malaria: Protocol for a Randomized Controlled Clinical Trial. JMIR Res Protoc (2016) 0.83
Hydroxycarbamide alters erythroid gene expression in children with sickle cell anaemia. Br J Haematol (2012) 0.82
Efficacy and safety of eculizumab in children and adolescents with paroxysmal nocturnal hemoglobinuria. Pediatr Blood Cancer (2014) 0.82
From infancy to adolescence: fifteen years of continuous treatment with hydroxyurea in sickle cell anemia. Medicine (Baltimore) (2014) 0.82
The diagnostic dilemma of congenital unstable hemoglobinopathies. Pediatr Blood Cancer (2010) 0.82
Asymmetrical closure of epiphyses in a patient with sickle cell anemia. J Pediatr Endocrinol Metab (2002) 0.81
Short stature in children with sickle cell anemia correlates with alterations in the IGF-I axis. J Pediatr Endocrinol Metab (2007) 0.81
IgA-mediated autoimmune hemolytic anemia in an infant. Pediatr Blood Cancer (2010) 0.81
Thrombopoiesis: new ITP paradigm? Blood (2011) 0.81
A novel G6PD mutation leading to chronic hemolytic anemia. Pediatr Blood Cancer (2008) 0.81
Effects of combined UDP-glucuronosyltransferase (UGT) 1A1*28 and 1A6*2 on paracetamol pharmacokinetics in beta-thalassemia/HbE. Pharmacology (2006) 0.80